A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (NCT04075266)
An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
This 2-year study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages ≥ 10 to ≤ 18 years with relapsing-remitting multiple sclerosis (RRMS). The data from this study will serve to determine the dosing regimen of ocrelizumab to be further investigated in the subsequent Phase III study in children and adolescents.
Who can join: Review the eligibility criteria below.
Location: University of Colorado Denver Childrens Hospital Rocky Mountain MS Center — Aurora, Colorado
Age range: 10 Years to 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- University of Colorado Denver Childrens Hospital Rocky Mountain MS Center — Aurora, Colorado
- Childrens National Health Center — Washington D.C., District of Columbia
- Boston Childrens Hospital — Boston, Massachusetts
- Washington Universtiy school of Medicine — St Louis, Missouri
- Cleveland Clinic — Cleveland, Ohio
- Ospedale Pediatrico Bambino Gesù — Rome, Lazio
- Azienda Ospedaliera Sant'Andrea — Rome, Lazio
- AOU Policlinico V. Emanuele - P.O G. Rodolico — Catania, Sicily
- Uniwersyteckie Centrum Kliniczne — Gda?sk,
- Uniwersytecki Szpital Kliniczny w Poznaniu — Późna,
- Dzieci?cy Szpital Kliniczny im. Józefa Polikarpa Brudzi?skiego — Warsaw,
- Instytut Pomnik Centrum Zdrowia Dziecka — Warsaw,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Sclerosis
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis — Birmingham, Alabama
- MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience — New Orleans, Louisiana
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Phoenix, Arizona
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Carlsbad, California
- The Synergistic Effects of AIH and FES in Persons With MS — Chicago, Illinois
- A Health Action Process Approach Online Intervention for People With Multiple Sclerosis — Champaign, Illinois
Explore by condition: All Multiple Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.